Skip to main content
KALA
NASDAQ Life Sciences

Former Major Shareholder Sells $306K in KALA BIO Stock, Reduces Stake Below 5%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.68
Mkt Cap
$31.231M
52W Low
$1.62
52W High
$1,030
52W Position info
3.7% above low
Off High info
100% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

KALA is trading near its 52-week low of $1.62 (3.7% above the low).

Summary

A former major investor in KALA BIO, David E. Lazar, sold over $300,000 worth of shares, reducing his stake below 5% following the company's recent reverse stock split and shelf registration.


Key Events · Ownership and Investor Activity · KALA

  • Significant Share Sales

    David E. Lazar sold 106,732 shares of common stock for total proceeds of approximately $306,564 across multiple transactions between May 4 and June 29, 2026. These sales represent a substantial portion of the company's market capitalization.

  • Reduced Ownership Below 5%

    The reporting person ceased to be a beneficial owner of more than 5% of KALA BIO's outstanding shares as of April 24, 2026, and has continued to reduce his stake through subsequent sales.

  • Post-Split Transactions

    All reported share numbers and prices in the transaction history are explicitly stated to be adjusted for the 1-for-50 reverse stock split effected by the Issuer on May 8, 2026.

  • Cost Basis of Remaining Shares

    The aggregate purchase price for the 719,404 shares currently held by Lazar (converted from Series AA Preferred Stock) was $1,308,007, implying an average cost of approximately $1.82 per share.


Analysis · KALA · Life Sciences

David E. Lazar, a former significant shareholder, has disclosed selling approximately $306,564 worth of KALA BIO common stock across multiple transactions between May and June 2026. These sales represent nearly 1% of the company's market capitalization and follow his cessation of beneficial ownership above 5% in April 2026. The continued reduction of his stake, particularly after the recent 1-for-50 reverse stock split and shelf registration, and while the stock is trading near its 52-week lows, indicates a lack of conviction from a major investor.

How filings like this one have moved

In the 30 days to Nov 8, 2026, 46.6% of the 1552 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.23%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KALA was trading at $1.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.2M. The 52-week trading range was $1.62 to $1,030.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KALA - Latest Insights

KALA
Sep 29, 2026, 7:30 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $0.474
Real-time Price: $0.1565 info
Change: -$0.3175 (-67%) info
Market Cap: $3.015M info
KALA
Sep 24, 2026, 4:10 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.5288
Real-time Price: $0.1565 info
Change: -$0.3723 (-70%) info
Market Cap: $3.015M info
KALA
Sep 11, 2026, 4:56 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.590
Real-time Price: $0.1565 info
Change: -$0.4335 (-73%) info
Market Cap: $3.015M info
KALA
Sep 03, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.538
Real-time Price: $0.1565 info
Change: -$0.3815 (-71%) info
Market Cap: $3.015M info
KALA
Aug 28, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.795
Real-time Price: $0.1565 info
Change: -$0.6385 (-80%) info
Market Cap: $3.015M info